SENTI-202 granted FDA orphan drug designation for blood cancers

SENTI-202 granted FDA orphan drug designation for blood cancers

Senti Biosciences‘ experimental cell therapy SENTI-202 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) as a potential therapy for hard-to-treat blood cancers, including acute myeloid leukemia (AML). The FDA gives this designation to experimental treatments for rare disorders to encourage investment in drugs, particularly when it may be harder for companies to recoup their costs and turn a profit. The desig…